Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
4 weeks: 1 vial uses 2 mL total
A phase III, randomized, double-blind, parallel-group study showed that the combination of SGLT2 inhibitors and DPP-4 inhibitors resulted in the reductions of HbA1c (mean baseline 7.908.02% [62.864.1 mmol/mol]), FPG, serum uric acid, SBP, and hypoglycemic risk were superior to those with the individual components in patients with T2DM
Documentation: Certificate of Analysis available where applicable
Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel
US$ 25.97
US$ 23.07
US$ 25.95
US$ 25.63
